Healthcare provider profile · identity verified

Delvis Ramirez, MD

General Practice · CABO ROJO, PR · NPI 1306982939

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Omeprazole	Omeprazole	367	82
Simvastatin	Simvastatin	363	124
Levothyroxine Sodium	Levothyroxine Sodium	335	100
Gabapentin	Gabapentin	316	80
Montelukast Sodium	Montelukast Sodium	280	90
Cilostazol	Cilostazol	241	83
Lisinopril	Lisinopril	238	66
Glimepiride	Glimepiride	208	62
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	199	57
Pantoprazole Sodium	Pantoprazole Sodium	196	57
Losartan Potassium	Losartan Potassium	169	52
Azithromycin	Azithromycin	160	107
Nabumetone	Nabumetone	158	88
Tamsulosin Hcl	Tamsulosin Hcl	154	50
Metformin Hcl	Metformin Hcl	153	50
Temazepam	Temazepam	132	26
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	129	47
Synthroid	Levothyroxine Sodium	128	38
Clonazepam	Clonazepam	126	17
Levofloxacin	Levofloxacin	113	86
Famotidine	Famotidine	112	26
Meclizine Hcl	Meclizine Hcl	112	35
Alprazolam	Alprazolam	111	21
Finasteride	Finasteride	102	31
Tradjenta	Linagliptin	101	23
Amlodipine Besylate	Amlodipine Besylate	99	35
Furosemide	Furosemide	99	39
Atorvastatin Calcium	Atorvastatin Calcium	96	42
Metformin Hcl Er	Metformin Hcl	92	33
Diclofenac Sodium	Diclofenac Sodium	87	29
Fluticasone Propionate	Fluticasone Propionate	85	29
Hydrochlorothiazide	Hydrochlorothiazide	83	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	77	24
Betamethasone Dipropionate	Betamethasone Dipropionate	75	33
Latanoprost	Latanoprost	73	12
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	72	55
Metoprolol Tartrate	Metoprolol Tartrate	71	26
Metoprolol Succinate	Metoprolol Succinate	63	22
Oxybutynin Chloride	Oxybutynin Chloride	62	25
Albuterol Sulfate Hfa	Albuterol Sulfate	61	21
Alendronate Sodium	Alendronate Sodium	61	19
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	61	23
Dicyclomine Hcl	Dicyclomine Hcl	59	21
Tramadol Hcl	Tramadol Hcl	58	28
Cephalexin	Cephalexin	57	48
Zolpidem Tartrate	Zolpidem Tartrate	57	11
Fenofibrate	Fenofibrate Nanocrystallized	56	22
Memantine Hcl	Memantine Hcl	56	13
Naproxen	Naproxen	55	18
Lorazepam	Lorazepam	54	suppressed
Ibuprofen	Ibuprofen	53	23
Clopidogrel	Clopidogrel Bisulfate	47	14
Allopurinol	Allopurinol	45	suppressed
Rivastigmine	Rivastigmine Tartrate	45	11
Farxiga	Dapagliflozin Propanediol	43	suppressed
Gemfibrozil	Gemfibrozil	42	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	42	15
Jardiance	Empagliflozin	42	suppressed
Albuterol Sulfate	Albuterol Sulfate	39	18
Rosuvastatin Calcium	Rosuvastatin Calcium	38	15
Amantadine	Amantadine Hcl	36	suppressed
Eliquis	Apixaban	35	suppressed
Baclofen	Baclofen	33	12
Glipizide	Glipizide	33	14
Quetiapine Fumarate	Quetiapine Fumarate	33	suppressed
Atenolol	Atenolol	32	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	32	suppressed
Mupirocin	Mupirocin	32	24
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	31	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Enalapril Maleate	Enalapril Maleate	27	suppressed
Nifedipine Er	Nifedipine	27	suppressed
Acyclovir	Acyclovir	26	suppressed
Loperamide	Loperamide Hcl	26	suppressed
Meloxicam	Meloxicam	26	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	24	14
Donepezil Hcl	Donepezil Hcl	24	suppressed
Methocarbamol	Methocarbamol	24	16
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Levetiracetam	Levetiracetam	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Trazodone Hcl	Trazodone Hcl	21	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Verapamil Er	Verapamil Hcl	20	suppressed
Lansoprazole	Lansoprazole	19	suppressed
Pentoxifylline	Pentoxifylline	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Folic Acid	Folic Acid	17	suppressed
Mupirocin	Mupirocin Calcium	17	14
Orphenadrine Citrate Er	Orphenadrine Citrate	17	15
Propranolol Hcl	Propranolol Hcl	17	suppressed
Carvedilol	Carvedilol	16	suppressed
Ciclopirox	Ciclopirox	16	suppressed
Clindamycin Hcl	Clindamycin Hcl	16	13
Irbesartan	Irbesartan	16	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	16	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	15	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	15	suppressed
Theophylline Er	Theophylline Anhydrous	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Ssd	Silver Sulfadiazine	14	suppressed
Sulfasalazine	Sulfasalazine	14	suppressed
Terconazole	Terconazole	14	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Effexor Xr	Venlafaxine Hcl	12	suppressed
Primidone	Primidone	12	suppressed
Risperidone	Risperidone	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error